Profile data is unavailable for this security.
About the company
JIANGZHONG PHARMACEUTICAL CO., LTD is a China-based company principally engaged in the manufacture, research and development and sales of over-the-counter (OTC) pharmaceuticals and healthcare products. The Company’s products include OTC medicines, healthcare products and functional food, as well as wine. Its OTC pharmaceuticals include indigestion tablets, lactobacillin tablets and sarcandra glabra tablets, among others. Its healthcare products and functional food include calcium tablets and ginseng products, among others. The Company mainly operates its businesses in domestic market.
- Revenue in CNY (TTM)4.30bn
- Net income in CNY734.24m
- Incorporated1996
- Employees4.01k
- LocationJiang Zhong Pharmaceutical Co LtdNo. 788, Huoju Avenue, High-Tech ZoneNANCHANG 330096ChinaCHN
- Phone+86 79 188169323
- Fax+86 79 188162532
- Websitehttps://www.jzjt.com/
More ▼
Mergers & acquisitions
| Acquired company | 600750:SHH since announced | Transaction value |
|---|---|---|
| Jiangxi Jiangzhong Changrun Pharmaceutical Co Ltd | 6.96% | 830.00k |
| Jiangxi Jiangzhong Herbal Health Technology Co Ltd | 6.96% | 1.06m |
Data delayed at least 15 minutes, as of Mar 13 2024 07:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liaoning Cheng Da Co Ltd | 11.18bn | 17.48m | 15.86bn | 3.36k | 797.69 | 0.5439 | -- | 1.42 | 0.013 | 0.013 | 7.34 | 19.07 | 0.2358 | 4.41 | 6.49 | 3,330,121.00 | -0.5366 | 3.59 | -0.7644 | 5.21 | 16.03 | 14.15 | -2.28 | 9.89 | 0.7792 | -- | 0.2834 | 15.93 | -25.97 | -10.97 | -80.95 | -21.26 | 7.04 | -- |
| Changchun BCHT Biotechnology Co | 1.92bn | 543.19m | 16.16bn | 1.24k | 29.69 | 3.95 | -- | 8.44 | 1.32 | 1.32 | 4.64 | 9.88 | 0.4116 | 0.8459 | 1.55 | 1,543,550.00 | 11.67 | 9.95 | 14.14 | 12.81 | 89.90 | 86.63 | 28.36 | 24.03 | 2.03 | -- | 0.0158 | 10.55 | 70.30 | 12.36 | 175.98 | 31.37 | 21.04 | -- |
| Jiang Zhong Pharmaceutical Co Ltd | 4.30bn | 734.24m | 16.78bn | 4.01k | 22.87 | 4.07 | -- | 3.90 | 1.17 | 1.17 | 6.83 | 6.55 | 0.6698 | 4.34 | 13.62 | 1,071,799.00 | 12.35 | 10.82 | 18.82 | 15.08 | 64.01 | 65.02 | 18.44 | 18.17 | 1.47 | -- | 0.0061 | 82.88 | 13.00 | 20.12 | 18.40 | 8.54 | 11.47 | 40.99 |
| KPC Pharmaceuticals Inc | 7.65bn | 432.35m | 17.20bn | 5.05k | 39.47 | 3.18 | -- | 2.25 | 0.5757 | 0.5757 | 10.20 | 7.15 | 0.8021 | 2.48 | 2.62 | 1,513,702.00 | 4.63 | 5.42 | 7.76 | 9.13 | 43.12 | 43.68 | 5.77 | 5.70 | 1.46 | 53.93 | 0.1688 | 35.75 | -6.99 | 1.64 | 16.05 | 5.79 | -21.33 | 14.87 |
| Shandong Buchang Pharmaceuticals Co Ltd | 12.37bn | -22.28m | 18.17bn | 8.31k | -- | 1.57 | -- | 1.47 | -0.0202 | -0.0202 | 11.18 | 10.46 | 0.5678 | 1.00 | 9.58 | 1,488,478.00 | -0.9013 | 3.26 | -1.30 | 4.72 | 64.05 | 74.71 | -1.59 | 4.85 | 0.5348 | 2.34 | 0.2522 | 121.01 | -11.41 | -0.6219 | 120.85 | -29.93 | -16.56 | -36.72 |
| Anhui Huaheng Biotechnology Co Ltd | 2.04bn | 454.44m | 18.66bn | 1.69k | 41.13 | 9.75 | -- | 9.15 | 2.88 | 2.88 | 12.92 | 12.15 | 0.6196 | 5.59 | 8.04 | 1,205,674.00 | 13.71 | 16.74 | 21.59 | 22.41 | 38.49 | 39.21 | 22.13 | 22.34 | 0.4552 | 155.98 | 0.4552 | 25.20 | 36.63 | 35.72 | 40.32 | 42.84 | 82.09 | -- |
| Dizal Jiangsu Pharmaceutical Co Ltd | 172.61m | -1.09bn | 18.73bn | 581.00 | -- | 26.88 | -- | 108.48 | -2.67 | -2.67 | 0.422 | 1.68 | 0.1008 | 0.3215 | 6.78 | 297,086.40 | -63.79 | -46.02 | -82.62 | -52.99 | 96.41 | 57.53 | -632.90 | -2,081.54 | 1.74 | -- | 0.4557 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
Data as of Mar 13 2024. Currency figures normalised to Jiang Zhong Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
17.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 30 Sep 2023 | 34.50m | 5.53% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2023 | 19.99m | 3.21% |
| China Investment Corp. (Investment Management)as of 30 Sep 2023 | 15.55m | 2.49% |
| Ping An Fund Management Co., Ltd.as of 30 Sep 2023 | 7.83m | 1.26% |
| Cinda Fund Management Co. Ltd.as of 30 Jun 2023 | 7.81m | 1.25% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2023 | 7.24m | 1.16% |
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2023 | 4.06m | 0.65% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2023 | 3.27m | 0.52% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 3.15m | 0.50% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 2.95m | 0.47% |
More ▼
Data from 30 Jun 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
